Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
BOTHELL, Wash., Aug. 31, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast a business overview and update by members of the management team at each of the following upcoming healthcare conferences:
- 11th Annual Wells Fargo Securities Healthcare Conference at 11:05 a.m. ET on Wednesday, September 7, 2016 in Boston, MA
- Morgan Stanley Global Healthcare Conference at 8:45 a.m. ET on Monday, September 12, 2016 in New York, NY
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://investor.alderbio.com/index.cfm, or by following the links below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
- Wells Fargo link: https://cc.talkpoint.com/well001/090716a_ae/?entity=36_OH41YUV
- Morgan Stanley link: https://cc.talkpoint.com/morg007/091216a_ae/?entity=4_REK0TUS
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide, a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Todd Davenport, Ph.D. Russo Partners, LLC (212) 845-4271 (212) 845-4235 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 [email protected]
